I stumbled across some potentially interesting news last nite when I met a fellow whose wife is a scientist for GSK. He said his wife believess the company will soon be dumping one of their cancer-treatment candidates due to recent poor clinical trial results. Could this open the door for them to seek a replacement candidate in their pipeline? A cursory look shows 6 cancer candidates already listed. I don't have time right now so I don't know which indications are being studied or which candidate recently concluded a trial, but I took the opportunity to sing the praises of LL, which intrigued him to the point of asking about CytoDyn. I mentioned how our former carnival barker/ CEO helped stymie progress and their desire to find a partner in BP. I'm conjecturing into outer space here thinking how cool it would be if he put a bug in his wife's ear and it travelled thru the grapevine to a decision-maker at GSK. But if we end up on GSK's acquisition radar, you can bet your last share that I'll be claiming as much credit as necessary for the merger!